Medgend Icon

Ledgend of Medicine







discontinued


Insulin

What is diabetes?

Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. The cells of your body need glucose for energy. A hormone called insulin helps the glucose get into your cells.

type 1 diabetestype 2 diabetes

What are the treatments for diabetes?

Treatments for diabetes can depend on the type. Common treatments include a diabetic meal plan, regular physical activity, and medicines. Some less common treatments are weight loss surgery for either type and an artificial pancreas or pancreatic islet transplantation for some people with type 1 diabetes.

Who needs diabetes medicines?

People with type 1 diabetes need to take a diabetes medicine called insulin to control their blood sugar.

Some people with type 2 diabetes can control their blood sugar with healthy food choices and physical activity. But for others, a diabetic meal plan and physical activity are not enough. They need to take diabetes medicines.

The kind of medicine you take depends on your type of diabetes, daily schedule, medicine costs, and any other health conditions that you have. Over time, you may need to take more than one diabetes medicine.

What are the types of medicines for type 1 diabetes?

If you have type 1 diabetes, you must take insulin because your body no longer makes it. There are different types of insulin that start to work at different speeds, and the effects of each last a different length of time. Your health care provider will measure your blood glucose to decide on the type of insulin. You may need to use more than one type.

You will also need to check your blood sugar at home. Your provider will tell you how often. The results of your blood sugar testing can help you make decisions about food, physical activity, and medicines.

You can take insulin several different ways. The most common are with a needle and syringe, an insulin pen, or an insulin pump. If you use a needle and syringe or a pen, you have to take insulin several times during the day, including with meals. An insulin pump gives you small, steady doses throughout the day. Less common ways to take insulin include inhalers, injection ports, and jet injectors.

In rare cases, taking insulin alone might not be enough to manage your blood sugar. Then you would need to take another diabetes medicine.

What are the types of medicines for type 2 diabetes?

There are several different medicines for type 2 diabetes. Each works in a different way. Many of them are pills. There are also medicines that you inject under your skin, such as insulin.

Over time, you may need more than one diabetes medicine to manage your blood sugar. You might add another diabetes medicine or switch to a combination medicine. A combination medicine contains more than one type of diabetes medicine in the same pill. Some people with type 2 diabetes take both pills and injections.

Even if you don't usually take insulin, you may need it at special times, such as during pregnancy or if you are in the hospital.

What else should I know about taking medicines for diabetes?

Even if you take medicines for diabetes, you still need to eat a healthy diet, stop smoking, take your other medicines, and get regular physical activity. These will help you manage your diabetes.

It is important to make sure that you understand your diabetes treatment plan. Talk to your provider about:

  • What your target blood sugar level is
  • What to do if your blood sugar gets too low or too high
  • Whether your diabetes medicines will affect other medicines you take
  • If you will have any side effects from the diabetes medicines

You should not change or stop your diabetes medicines on your own. Talk to your provider first.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Insulin FDA Approved Drugs

ACTOS [Pioglitazone HydrochlorideC19H20N2O3SClH]
RX
-
eq 15mg base (oral tablet)
eq 30mg base (oral tablet)
eq 45mg base (oral tablet)
Takeda Pharms UsaJul 15, 1999
  • Method of reducing side effects of active components admin to a diabetic by admin a chemical compound having formula (incl pioglitazone) in combination with an insulin secretion enhancer.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

AFREZZA [Insulin Recombinant Human]
RX
-
12 units/inh (inhalation powder)
4 units/inh (inhalation powder)
8 units/inh (inhalation powder)
MannkindApr 17, 2015
  • Administration of a composition comprising insulin complexed with a diketopiperazine..
  • Administration of a composition comprising insulin complexed with microparticles of a diketopiperazine..
  • Administration of fdkp microparticles comprising insulin..
  • Method of aerosolizing/deagglomerating an insulin dry powder for use in treating diabetes mellitus via oral inhalation using an inhaler with a cartridge containing the insulin dry powder..
  • Method of controlling glycemia in diabetics by administering an initial dose of insulin-fdkp with a meal; determining blood glucose level 1-2 hrs after and administering a supplemental dose of insulin-fdkp if postprandial glucose level is >140 mg/dl.
  • Method of delivering to a patient with diabetes mellitus in a single inhalation, greater than 75% of a dry powder dose comprising insulin and fumaryl diketopiperazine using a high resistance to flow dry powder inhaler..
  • Pulmonary administration of a compisition comprising insulin bound to a diketopiperazine..
  • Pulmonary administration of a composition comprising insulin bound to a complexing agent..
  • Pulmonary administration of an insulin composition comprising fdkp at the beginning of a meal to a patient also being treated with a long-acting insulin..
  • Treatment of a patient having diabetes mellitus with a prandial rapid acting insulin..
  • Treatment of diabetes mellitus with an inhaled insulin to improve glycemic control using a dry powder inhalation system comprising an inhaler, a cartridge and a dry powder medicament comprising insulin in a single inhalation.
  • Treatment of patient having diabetes mellitus via oral inhalation of fdkp microparticles comprising insulin.
  • Use of an inhaler to administer dry powder medicament.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

APIDRA [Insulin Glulisine Recombinant]
RX
-
1000 units/10ml (100 units/ml) (iv (infusion), subcutaneous injectable)
300 units/3ml (100 units/ml) (iv (infusion), subcutaneous injectable)
Sanofi Aventis UsApr 16, 2004
  • Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
  • Method of treating a patient suffering from diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

APIDRA SOLOSTAR [Insulin Glulisine Recombinant]
RX
-
300 units/3ml (subcutaneous injectable)
Sanofi Aventis UsFeb 24, 2009
  • Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
  • Method of treating a patient suffering from diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BASAGLAR [Insulin GlargineC267H404N72O78S6]
RX
-
300 units/3ml (100 units/ml) (subcutaneous solution)
Eli Lilly And CoDec 16, 2015
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BYDUREON [Exenatide Synthetic]
RX
-
2mg/vial (subcutaneous for suspension, extended release)
Astrazeneca AbJan 27, 2012
  • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
  • Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
  • Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
  • Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
  • Reductions in body weight are observed with exenatide.
  • Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
  • Treatment of type 2 diabetes.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BYDUREON PEN [Exenatide Synthetic]
RX
-
2mg (subcutaneous for suspension, extended release)
Astrazeneca AbFeb 28, 2014
  • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
  • Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
  • Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
  • Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
  • Reductions in body weight are observed with exenatide.
  • Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
  • Treatment of type 2 diabetes.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BYETTA [Exenatide Synthetic]
RX
-
300mcg/1.2ml (250mcg/ml) (subcutaneous injectable)
600mcg/2.4ml (250mcg/ml) (subcutaneous injectable)
Astrazeneca AbApr 28, 2005
  • Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
  • Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
  • Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
  • Stimulating insulin release by administering exenatide.
  • Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
  • Use of exenatide may result in reduction in appetite..
  • Use of exenatide may result in reduction in body weight.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

CONTRAVE [Bupropion HydrochlorideC13H18ClNOClH : Naltrexone HydrochlorideC20H23NO4ClH]
RX
-
90mg : 8mg (oral tablet, extended release)
OrexigenSep 10, 2014
  • For chronic weight management for treating overweight or obesity.
  • For effect on blood glucose parameters in patients with insulin resistance.
  • Use of naltrexone and bupropion based on an escalating dose schedule.
  • Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder.
  • Use of naltrexone and bupropion in a layered formulation for chronic weight management for affecting weight loss.
  • Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

CYCLOSET [Bromocriptine MesylateC32H40BrN5O5CH4O3S]
RX
-
eq 0.8mg base (oral tablet)
VeroscienceMay 5, 2009
  • Administration once daily within two hours after waking in the morning for improvement of glycemic control in a type 2 diabetes patient.
  • Improvement of glycemic control in individuals with type 2 diabetes.
  • Improvements of glycemic control in individuals with type 2 diabetes who have one or more specified cardiovascular risk factors.
  • Treatment of type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue wherein the combined therapeutic effect is greater than the additive effect of administering each agent alone.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

FARXIGA [Dapagliflozin PropanediolC21H25ClO6C3H8O2H2O]
RX
-
eq 10mg base (oral tablet)
eq 5mg base (oral tablet)
Astrazeneca AbJan 8, 2014
  • Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone.
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

GLYXAMBI [EmpagliflozinC23H27ClO7 : LinagliptinC25H28N8O2]
RX
-
10mg : 5mg (oral tablet)
25mg : 5mg (oral tablet)
Boehringer IngelheimJan 30, 2015
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea).
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without metformin).
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin.
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMALOG [Insulin Lispro Recombinant]
RX
-
100 units/ml (injection injectable)
LillyJun 14, 1996
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMALOG KWIKPEN [Insulin Lispro Recombinant]
RX
-
100 units/ml (injection injectable)
200 units/ml (subcutaneous solution)
LillySep 6, 2007
Eli Lilly And CoMay 26, 2015
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMALOG MIX 50/50 [Insulin Lispro Protamine Recombinant : Insulin Lispro Recombinant]
RX
-
50 units/ml : 50 units/ml (injection injectable)
LillyDec 22, 1999
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMALOG MIX 50/50 KWIKPEN [Insulin Lispro Protamine Recombinant : Insulin Lispro Recombinant]
RX
-
50 units/ml : 50 units/ml (injection injectable)
LillySep 6, 2007
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMALOG MIX 75/25 [Insulin Lispro Protamine Recombinant : Insulin Lispro Recombinant]
RX
-
75 units/ml : 25 units/ml (injection injectable)
LillyDec 22, 1999
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMALOG MIX 75/25 KWIKPEN [Insulin Lispro Protamine Recombinant : Insulin Lispro Recombinant]
RX
-
75 units/ml : 25 units/ml (injection injectable)
LillySep 6, 2007
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMULIN 70/30 [Insulin Recombinant Human : Insulin Susp Isophane Recombinant Human]
OTC
-
30 units/ml : 70 units/ml (injection injectable)
LillyApr 25, 1989
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMULIN 70/30 PEN [Insulin Recombinant Human : Insulin Susp Isophane Recombinant Human]
OTC
-
30 units/ml : 70 units/ml (injection injectable)
LillyAug 6, 1998
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMULIN N [Insulin Susp Isophane Recombinant Human]
OTC
-
100 units/ml (injection injectable)
LillyOct 28, 1982
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMULIN R [Insulin Recombinant Human]
OTC
-
100 units/ml (injection injectable)
LillyOct 28, 1982
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMULIN R [Insulin HumanC257H383N65O77S6]
RX
-
10000 units/20ml (500 units/ml) (subcutaneous solution)
LillyMar 31, 1994
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMULIN R KWIKPEN [Insulin HumanC257H383N65O77S6]
RX
-
1500 units/3ml (500 units/ml) (subcutaneous solution)
LillyDec 29, 2015
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMULIN R PEN [Insulin Recombinant Human]
OTC
-
100 units/ml (injection injectable)
LillyAug 6, 1998
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

JANUMET [Metformin HydrochlorideC4H11N5ClH : Sitagliptin PhosphateC16H15F6N5OH2OH3O4P]
RX
-
1gm : eq 50mg base (oral tablet)
500mg : eq 50mg base (oral tablet)
Merck Sharp DohmeMar 30, 2007
  • Improvement of glycemic control in adults with type 2 diabetes mellitus.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

JANUVIA [Sitagliptin PhosphateC16H15F6N5OH2OH3O4P]
RX
-
eq 100mg base (oral tablet)
eq 25mg base (oral tablet)
eq 50mg base (oral tablet)
Merck Sharp DohmeOct 16, 2006
  • Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin and/or a ppar-gamma agonist and/or sulfonylurea and/or insulin.
  • Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin..
  • Improvement of glycemic control in adults with type 2 diabetes mellitus.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidaste-iv inhibitor.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

KAZANO [Alogliptin BenzoateC18H21N5O2C7H6O2 : Metformin HydrochlorideC4H11N5ClH]
RX
-
eq 12.5mg base : 1gm (oral tablet)
eq 12.5mg base : 500mg (oral tablet)
Takeda Pharms UsaJan 25, 2013
  • Method of treating diabetes comprising administering a compound such as alogliptin.
  • Method of treating diabetes comprising administering alogliptin.
  • Methods of lowering elevated post prandial blood glucose levels comprising administering a dipeptidyl peptidase inhibitor.
  • Methods of modifying glucose metabolism and treating diabetes comprising administering a dipeptidyl peptidase inhibitor and one or more other therapeutic agents such as metformin.
  • Methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer.
  • Methods of treating diabetes comprising administering a dipeptidyl peptidase inhibitor and metformin.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LANTUS [Insulin Glargine Recombinant]
RX
-
100 units/ml (injection injectable)
Sanofi Aventis UsApr 20, 2000
  • Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LANTUS SOLOSTAR [Insulin Glargine Recombinant]
RX
-
300 units/3ml (100 units/ml) (injection injectable)
Sanofi Aventis UsApr 27, 2007
  • Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LEVEMIR [Insulin Detemir Recombinant]
RX
-
1000 units/10ml (100 units/ml) (subcutaneous injectable)
Novo Nordisk IncJun 16, 2005
  • Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LEVEMIR FLEXTOUCH [Insulin Detemir Recombinant]
RX
-
300 units/3ml (100 units/ml) (subcutaneous injectable)
Novo Nordisk IncOct 31, 2013
  • Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NESINA [Alogliptin BenzoateC18H21N5O2C7H6O2]
RX
-
eq 12.5mg base (oral tablet)
eq 25mg base (oral tablet)
eq 6.25mg base (oral tablet)
Takeda Pharms UsaJan 25, 2013
  • Method of treating diabetes comprising administering a compound such as alogliptin.
  • Method of treating diabetes comprising administering alogliptin.
  • Methods of lowering elevated post prandial blood glucose levels comprising administering a dipeptidyl peptidase inhibitor.
  • Methods of modifying glucose metabolism and treating diabetes comprising administering a dipeptidyl peptidase inhibitor and one or more other therapeutic agents such as metformin.
  • Methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer.
  • Methods of treating diabetes comprising administering a dipeptidyl peptidase inhibitor and metformin.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NOVOLIN 70/30 [Insulin Recombinant Human : Insulin Susp Isophane Recombinant Human]
OTC
-
30 units/ml : 70 units/ml (injection injectable)
Novo Nordisk IncJun 25, 1991
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NOVOLIN N [Insulin Susp Isophane Recombinant Human]
OTC
-
100 units/ml (injection injectable)
Novo Nordisk IncJul 1, 1991
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NOVOLIN R [Insulin Recombinant Human]
OTC
-
100 units/ml (injection injectable)
Novo Nordisk IncJun 25, 1991
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NOVOLOG [Insulin Aspart Recombinant]
RX
-
1000 units/10ml (100 units/ml) (subcutaneous injectable)
Novo Nordisk IncJun 7, 2000
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NOVOLOG FLEXPEN [Insulin Aspart Recombinant]
RX
-
300 units/3ml (100 units/ml) (subcutaneous injectable)
Novo Nordisk IncJan 19, 2001
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NOVOLOG FLEXTOUCH [Insulin Aspart Recombinant]
RX
-
300 units/3ml (100 units/ml) (subcutaneous injectable)
Novo Nordisk IncOct 31, 2013
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NOVOLOG MIX 70/30 [Insulin Aspart Protamine Recombinant : Insulin Aspart Recombinant]
RX
-
700 units/10ml : 300 units/10ml (70 units/ml : 30 units/ml) (subcutaneous injectable)
Novo Nordisk IncNov 1, 2001
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NOVOLOG MIX 70/30 FLEXPEN [Insulin Aspart Protamine Recombinant : Insulin Aspart Recombinant]
RX
-
210 units/3ml : 90 units/3ml (70 units/ml : 30 units/ml) (subcutaneous injectable)
Novo Nordisk IncMay 3, 2002
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NOVOLOG PENFILL [Insulin Aspart Recombinant]
RX
-
300 units/3ml (100 units/ml) (subcutaneous injectable)
Novo Nordisk IncJun 7, 2000
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ONGLYZA [Saxagliptin HydrochlorideC18H25N3O2ClH]
RX
-
eq 2.5mg base (oral tablet)
eq 5mg base (oral tablet)
Astrazeneca AbJul 31, 2009
  • Method for treating type ii diabetes by administering saxagliptin.
  • Method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazolidinedione, glyburide or metformin plus a sulfonylurea.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

OSENI [Alogliptin BenzoateC18H21N5O2C7H6O2 : Pioglitazone HydrochlorideC19H20N2O3SClH]
RX
-
eq 12.5mg base : eq 15mg base (oral tablet)
eq 12.5mg base : eq 30mg base (oral tablet)
eq 12.5mg base : eq 45mg base (oral tablet)
eq 25mg base : eq 15mg base (oral tablet)
eq 25mg base : eq 30mg base (oral tablet)
eq 25mg base : eq 45mg base (oral tablet)
Takeda Pharms UsaJan 25, 2013
  • Method of treating diabetes comprising administering a compound such as alogliptin.
  • Method of treating diabetes comprising administering alogliptin.
  • Methods of lowering elevated post prandial blood glucose levels comprising administering a dipeptidyl peptidase inhibitor.
  • Methods of modifying glucose metabolism and treating diabetes comprising administering a dipeptidyl peptidase inhibitor and one or more other therapeutic agents such as metformin.
  • Methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer.
  • Methods of treating diabetes comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer.
  • Methods of treating diabetes comprising administering a dipeptidyl peptidase inhibitor and metformin.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

RYZODEG 70/30 [Insulin AspartC256H381N65O79S6 : Insulin DegludecC274H411N65O81S6]
RX
-
90 units/3ml : 210 units/3ml (30 units/ml : 70 units/ml) (subcutaneous solution)
Novo Nordisk IncSep 25, 2015
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SOLIQUA 100/33 [Insulin GlargineC267H404N72O78S6 : Lixisenatide]
RX
-
300 units/3ml : 99mcg/3ml (100 units/ml : 33mcg/ml) (subcutaneous solution)
Sanofi-aventis UsNov 21, 2016
  • Improvement in glycemic control in adults with type 2 diabetes mellitus inadequately controlled by basal insulin or lixisenatide by use of a pen injector with a threaded drive sleeve.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SYMLIN [Pramlintide AcetateC171H267N51O53S2C2H4O2H2O]
RX
-
eq 1.5mg base/1.5ml (eq 1mg base/ml) (subcutaneous injectable)
eq 2.7mg base/2.7ml (eq 1mg base/ml) (subcutaneous injectable)
Astrazeneca AbSep 25, 2007
  • Treatment of diabetes with an amylin agonist, including with insulin.
  • Treatment of diabetes with an amylin agonist.
  • Use of an amylin agonist to reduce gastric motility and treat post prandial hypergylcemia.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TOUJEO SOLOSTAR [Insulin Glargine Recombinant]
RX
-
300 units/ml (300 units/ml) (subcutaneous solution)
Sanofi Us ServicesFeb 25, 2015
  • Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
  • Improvement in glycemic control in diabetes mellitus patients.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TRADJENTA [LinagliptinC25H28N8O2]
RX
-
5mg (oral tablet)
Boehringer IngelheimMay 2, 2011
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidaste-iv inhibitor.
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone).
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.
  • Method of treating type 2 diabetes mellitus by administering linagliptin.
  • Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin.
  • Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin.
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TRESIBA [Insulin DegludecC274H411N65O81S6]
RX
-
300 units/3ml (100 units/ml) (subcutaneous solution)
600 units/3ml (200 units/ml) (subcutaneous solution)
Novo Nordisk IncSep 25, 2015
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

XIGDUO XR [Dapagliflozin PropanediolC21H25ClO6C3H8O2H2O : Metformin HydrochlorideC4H11N5ClH]
RX
-
eq 10mg base : 1gm (oral tablet, extended release)
eq 10mg base : 500mg (oral tablet, extended release)
eq 5mg base : 1gm (oral tablet, extended release)
eq 5mg base : 500mg (oral tablet, extended release)
Astrazeneca AbOct 29, 2014
  • Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone.
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

XULTOPHY 100/3.6 [Insulin DegludecC274H411N65O81S6 : LiraglutideC172H265N43O51]
RX
-
300 units/3ml : 10.8mg/3ml (100 units/ml : 3.6mg/ml) (subcutaneous solution)
Novo Nordisk IncNov 21, 2016
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.